Whipps Cross Hospital, Barts Health NHS Trust, London, U.K.
Women's Health Research Unit, Queen Mary University of London, London, U.K.
In Vivo. 2019 Sep-Oct;33(5):1393-1401. doi: 10.21873/invivo.11616.
Power morcellation remains one of the most significant developments in minimal access surgery over the past decade, allowing many more patients to benefit from the least invasive surgical route. However, its use is not without controversy, particularly with regards to the risks of an undiagnosed leiomyosarcoma. Increased media and, in particular, on-going social media coverage since events in 2014 have only served to intensify the debate, culminating in the Food and Drug Administration essentially 'banning' its use in the USA. Practice however continues to vary and this technique remains widely used in Europe and in particular the UK. The aim of this article was to review the development of power morcellation in gynaecology and the underlying risks, including that of undiagnosed leiomyosarcoma, as well as appraise the evolving literature on patient awareness and informed consent and the wider implications of morcellation restriction.
电动切割仍然是过去十年微创外科领域最重要的进展之一，使更多的患者能够受益于创伤最小的手术途径。然而，它的使用并非没有争议，特别是在未诊断的平滑肌肉瘤的风险方面。自 2014 年以来，媒体，特别是社交媒体的持续报道，只会加剧这场争论，最终导致美国食品和药物管理局实质上“禁止”在美国使用该技术。然而，实践中仍然存在差异，这种技术在欧洲，特别是在英国仍然被广泛使用。本文的目的是回顾妇科电动切割的发展及其潜在风险，包括未诊断的平滑肌肉瘤，以及评估关于患者意识和知情同意的不断发展的文献，以及限制切割的更广泛影响。
